Results 161 to 170 of about 879,926 (306)
Neural Regulation of Cardiac Arrhythmias: From the Brain-Heart Axis to Emerging Precision Therapies. [PDF]
Xia Y, Han Y, Yu T, Ni L, Wang D.
europepmc +1 more source
Sudden Cardiac Death, a leading cause of death in Canada, commonly occurs as a result of arrhythmias occurring in the first hour of acute regional ischemia (ARI) after coronary artery occlusion.
Baumeister, Peter
core
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley +1 more source
Advances in autonomic neuromodulation for cardiac arrhythmias: Shifting paradigms in pathophysiology and therapeutics. [PDF]
Rajendran PS, Ajijola OA.
europepmc +1 more source
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer +25 more
wiley +1 more source
When the Heart Pays for the Chest: A Case Report of an Extracardiac Mediastinal Mass Presenting With Cardiac Arrhythmias. [PDF]
El Khadir L +4 more
europepmc +1 more source
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García +17 more
wiley +1 more source
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang +3 more
wiley +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen +7 more
wiley +1 more source

